Generic Ibtrozi Availability

Last updated on Jul 9, 2025.

Ibtrozi is a brand name of taletrectinib, approved by the FDA in the following formulation(s):

IBTROZI (taletrectinib adipate - capsule;oral)

• Manufacturer: NUVATION
  Approval date: June 11, 2025
  Strength(s): EQ 200MG BASE ^[RLD]

Is there a generic version of Ibtrozi available?

No. There is currently no therapeutically equivalent version of Ibtrozi available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Ibtrozi. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQ.

Related patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• Imidazo[1,2-b]pyridazine derivatives as kinase inhibitors
  Patent 9,187,489
  Issued: November 17, 2015
  Inventor(s): Takeda; Yasuyuki et al.
  Assignee(s): Daiichi Sankyo Company, Limited (Chuo-ku, JP)
  

  The present invention is intended to provide a compound or a pharmacologically acceptable salt thereof which is useful in the treatment of a tumor through its ROS1 kinase enzyme activity inhibitory effect and NTRK kinase enzyme inhibitory effect. The present invention provides a compound having an imidazo[1,2-b]pyridazine structure represented by the general formula (I) or a pharmacologically acceptable salt thereof, and a pharmaceutical composition comprising the compound. In the formula, R.sup.1, G, T, Y.sup.1, Y.sup.2, Y.sup.3, and Y.sup.4 are as defined herein.

  Patent expiration dates:

  • June 3, 2033
    
    ✓ 
    Patent use: TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC ROS1-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC)
    ✓ 
    Drug substance
    ✓ 
    Drug product
• Imidazo[1,2-b]pyridazine derivatives as kinase inhibitors
  Patent 9,751,887
  Issued: September 5, 2017
  Inventor(s): Takeda; Yasuyuki et al.
  Assignee(s): Daiichi Sankyo Company, Limited (Chuo-ku, JP)
  

  The present invention is intended to provide a compound or a pharmacologically acceptable salt thereof which is useful in the treatment of a tumor through its ROS1 kinase enzyme activity inhibitory effect and NTRK kinase enzyme inhibitory effect. The present invention provides a compound having an imidazo[1,2-b]pyridazine structure represented by the general formula (I) or a pharmacologically acceptable salt thereof, and a pharmaceutical composition comprising the compound. In the formula, R.sup.1, G, T, Y.sup.1, Y.sup.2, Y.sup.3, and Y.sup.4 are as defined herein.

  Patent expiration dates:

  • June 3, 2033
    
    ✓ 
    Patent use: TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC ROS1-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC)
    ✓ 
    Drug substance
    ✓ 
    Drug product

Related exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:

  • June 11, 2030 - NEW CHEMICAL ENTITY

Related/similar drugs

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer